Repositioning Sarcoidosis from a Vague Comorbidity on the Preoperative Problem List to a Prototype Condition for Precision Perioperative Medicine
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Recently, our research team has published a focused perioperative risk assessment of sarcoidosis, building a pathophysiological and practical framework for risk assessment of rare disorders.[1] Reading through a precision lens, we argue that who the sarcoidosis patient is, in terms of organ involvement, inflammatory activity, treatment, and functional reserve, matters as much as what surgery they are having and that risk mitigation needs to extend well into recovery rather than stopping at the operating room exit door. This publication, and a forthcoming evidence-infused review,[2] seeks to deconstruct rare disorders into distinct perioperative phenotypes. It foregrounds how granulomatous inflammation can involve the lungs, heart, airway, nervous system, liver, calcium metabolism, and the immune axis, with each domain representing a different risk signature under anesthesia and surgical stress. That mapping aligns with broader sarcoidosis literature that already recognizes phenotypic heterogeneity and variable prognosis.[3] For perioperative clinicians, this seismic shift, facilitated by advanced electronic medical record systems and artificial intelligence, reframes the question from “does the patient have sarcoidosis?” to “which sarcoidosis phenotype is this, and what are the modifiable perioperative hazards attached to this phenotype?” The perioperative complication manuscript then takes the next step: documenting actual postoperative morbidity in patients with sarcoidosis undergoing surgery. Even without reliance on specific numeric effect sizes, the structure of the work is critical for improving the recognition of sarcoidosis-specific complications. By cataloguing pulmonary, cardiac, infectious, and other complications against preexisting disease features, it shows that sarcoidosis is not a benign background condition and unmasks the predictability of postoperative complications. Sarcoidosis, and likely other rare disorders, is associated with a measurable burden of adverse events, and those events are plausibly enriched in subgroups with advanced pulmonary disease, cardiac involvement, or significant immunosuppression, patterns consistent with what is known about the natural history of organ-specific phenotypes in this disease.[4] Interpreting those data through a precision medicine lens, the paper effectively validates the idea that “one size fits all” perioperative pathways are inadequate for this population, and likely many others. Accordingly, our study invites the perioperative medicine community to define perioperative risk phenotypes more explicitly. For example, we included patients with cardiac sarcoidosis or suspected occult cardiac involvement: conduction system disease, ventricular arrhythmias, reduced ejection fraction, or prior granulomatous lesions on cardiac magnetic resonance imaging (MRI) or positron emission tomography (PET) scan. In these patients, perioperative risk signal unmasks as sudden decompensations and hemodynamic fragility. A second phenotype comprises those with fibrotic pulmonary sarcoidosis and/or pulmonary hypertension, where hypoxemia, right ventricular strain, and ventilator dependence become the main concerns.[5] A third phenotype may comprise those with airway and ear, nose, and throat involvement (laryngeal, tracheobronchial disease, or cervical lymphadenopathy), in whom difficult mask ventilation, intubation, and peri-extubation obstruction predominate. A fourth may involve systemic immunosuppression, in which infections and immunosuppressant-related metabolic complications are central [see Figure 1].Figure 1: Precision perioperative phenotyping in sarcoidosis. Schematic illustrating how a diagnosis of sarcoidosis is decomposed into key clinically relevant perioperative phenotypes: cardiac sarcoidosis, fibrotic lung disease/pulmonary hypertension, treatment-related immunosuppression, and airway/ear, nose, and throat involvement. Upward arrows depict the identification and phenotyping of patients in the preoperative period, while dashed arrows indicate appropriate linkage of the phenotype to select “optimal” perioperative pathways. This precision preoperative phenotyping framework supports the research and development of targeted risk mitigation strategies that extend into the postoperative phasePrecision perioperative medicine is, at its core, about making these phenotypes operational and actionable. On the preoperative side, the manuscripts implicitly argue against untargeted “more testing” and for selective, phenotype-driven evaluation. For a cardiac sarcoid phenotype, that may mean relying heavily on advanced cardiac imaging (echocardiography, cardiac MRI, and FDG-PET) and rhythm surveillance before intermediate or high-risk surgery, while avoiding routine stress testing in patients with low risk probability. For fibrotic pulmonary disease, the focus shifts to spirometry, diffusing capacity of the lungs for carbon monoxide, and exercise tolerance, mirroring broader evidence that lung function and functional capacity predict pulmonary complications. The risk mitigation strategies that follow naturally become phenotype-specific. Cardiac sarcoid patients may benefit from preemptive device optimization (pacemaker/implantable cardioverter defibrillator checks), perioperative electrophysiology input, avoidance of QT interval (cardiac)-prolonging drugs, and aggressive electrolyte management.[6,7] Those with advanced pulmonary sarcoidosis might be triaged toward regional techniques when feasible, lung-protective ventilation, cautious fluid balance, and planned high-dependency or intensive care unit admission for early postoperative support. Airway sarcoidosis may warrant awake fiberoptic intubation, smaller-diameter endotracheal tubes, and controlled extubation. Immunosuppressed patients need thoughtful steroid dosages, infection prophylaxis, and glucose control. Crucially, both manuscripts shift decision-making into the postoperative recovery continuum, which is often the weakest link in traditional perioperative care models. If sarcoidosis phenotypes confer sustained vulnerability, then risk-adjusted monitoring and follow-up become part of the precision approach, not simply an afterthought. From a systems perspective, this underscores that precision perioperative medicine is not just about better risk scoring; it is about structured recovery pathways that encode phenotypes into workflows. The logical next steps are the creation of perioperative sarcoidosis pathways and order sets with standardized prompts, decision trees for when to order advanced imaging, criteria for postoperative level-of-care decisions, and default bundles for phenotypes. Over time, linking these structured phenotypes with prospectively collected outcome data will enable more formal predictive models and, ultimately, machine learning–based decision support, echoing broader movements in perioperative data science that is speculative but consistent with the field’s trajectory. There are limitations intrinsic to the literature on sarcoidosis perioperative that temper how far we can generalize. Most datasets are relatively small, frequently single-center, and inherently confounded by indication as patients with more severe disease are more likely to received more testing and also the ones at higher risk. Our study is unlikely to fully disentangle disease activity, chronic damage, and treatment effects from the independent impact of surgery type and urgency. Nevertheless, in precision perioperative medicine, perfect calibration is less important than correctly identifying who is sufficiently high risk to justify intervention. Even moderate-quality evidence that certain sarcoidosis phenotypes cluster with specific adverse events is sufficient to justify more systematic phenotyping and proactive mitigation. Ultimately, these two manuscripts collectively make the case for using sarcoidosis as a model disease for precision perioperative medicine. Its multi-organ nature, variable trajectory, and wide spectrum of severity make sarcoidosis an ideal testbed for phenotype-based approaches that could later be generalized to other complex inflammatory or multisystem conditions. The traced conceptual arc, from pathophysiological understanding to observed perioperative outcomes, to phenotype-driven risk mitigation that extends into postoperative recovery, is exactly the arc that precision perioperative medicine seeks to follow. What remains is the work of cost-effective operationalization: embedding these insights into triage algorithms and clinical pathways that continuously refine care for these special and vulnerable populations. Acknowledgment None. Author contributions ZJC: conceptualization, formal analysis, writing-original draft, and writing-review and editing. AR: writing-review and editing. Data availability statement No new dataset was generated for this article. Ethical policy and Institutional Review Board statement Not applicable. Consent to participate Not applicable. Financial support and sponsorship Nil. Conflicts of interest ZJC has industry funding for research involving preoperative submaximal cardiopulmonary exercise testing unrelated to the present work (Shape Medical Systems Inc., St. Paul, MN, USA) and royalties from the following publishers: UpToDate (Waltham, MA, USA) and Wolters Kluwer (Alphen aan den Rijn, The Netherlands). AR, MJL, and NIB have nothing to disclose.
Fields of Study & Subjects
Sarcoidosis and Beryllium Toxicity Research
Cardiac
Anesthesia and Surgical Outcomes
Lung Cancer Diagnosis and Treatment
Publication details
- Journal / source
- Bali Journal of Anesthesiology
- Volume
- 10
- Issue
- 1
- Pages
- 1–3
- Publication date
- 1 January 2026
- Language
- EN